- 作者: I-Jung Lee, Cheng-Pu Sun, Ping-Yi Wu, Yu-Hua Lan, I-Hsuan Wang, Wen-Chun Liu, Joyce Pei-Yi Yuan, Yu-Wei Chang, Sheng-Che Tseng, Szu-I Tsung, Yu-Chi Chou, Monika Kumari, Yin-Shiou Lin, Hui-Feng Chen, Tsung-Yen Chen, Chih-Chao Lin, Chi-Wen Chiu, Chung-Hsuan Hsieh, Cheng-Ying Chuang, Chao-Min Cheng, Hsiu-Ting Lin, Wan-Yu Chen, Fu-Fei Hsu, Ming-Hsiang Hong, Chun-Che Liao, Chih-Shin Chang, Jian-Jong Liang, Hsiu-Hua Ma, Ming-Tsai Chiang, Hsin-Ni Liao, Hui-Ying Ko, Liang-Yu Chen, Yi-An Ko, Pei-Yu Yu, Tzu-Jing Yang, Po-Cheng Chiang, Shang-Te Hsu, Yi-Ling Lin, Chong-Chou Lee, Han-Chung Wu & Mi-Hua Tao
- 作者服務機構: 1.Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan 2.Department of Clinical Laboratory Science and Medical Biotechnology, National Taiwan University, Taipei, Taiwan 3.Genomics Research Center, Academia Sinica, Taipei, Taiwan 4.Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan 5.Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan 6.Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan 7.Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan
- 中文摘要:
- 英文摘要:
Background: With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and
immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efcacy.
Methods: We report an mRNA-based vaccine using an engineered “hybrid” receptor binding domain (RBD) that
contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants.
Results: A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high
titers of broadly neutralizing antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid
vaccine generated strong Omicron-specifc neutralizing antibodies as well as low but signifcant titers against other
VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild
type and all VOCs.
Conclusions: These results demonstrate that inclusion of diferent antigenic mutations from various SARS-CoV-2
variants is a feasible approach to develop cross-protective vaccines. - 中文關鍵字:
- 英文關鍵字: Omicron vaccine, mRNA vaccine, SARS-CoV-2, COVID-19, Variants of concern, Hybrid vaccine, Booster dose, Next generation vaccine, Cross-protectivity